1	VEGF165	VEGF165	B-NP	NN	B-protein	9	SUB	-1
2	expressed	express	B-VP	VBN	O	1	NMOD	9	expressed
3	by	by	B-PP	IN	O	2	VMOD	-1
4	a	a	B-NP	DT	O	8	NMOD	-1
5	replication-deficient	replication-deficient	I-NP	JJ	O	8	NMOD	-1
6	recombinant	recombinant	I-NP	JJ	O	8	NMOD	-1
7	adenovirus	adenovirus	I-NP	NN	O	8	NMOD	-1
8	vector	vector	I-NP	NN	O	3	PMOD	-1
9	induces	induce	B-VP	VBZ	O	0	ROOT	17	induces
10	angiogenesis	angiogenesis	B-NP	NN	O	9	OBJ	3	angiogenesis
11	in	in	B-ADVP	FW	O	9	VMOD	-1
12	vivo	vivo	I-ADVP	FW	O	11	AMOD	-1
13	.	.	O	.	O	9	P	-1

1	To	To	B-VP	TO	O	2	VMOD	-1
2	evaluate	evaluate	I-VP	VB	O	0	ROOT	-1
3	the	the	B-NP	DT	O	4	NMOD	-1
4	concept	concept	I-NP	NN	O	2	OBJ	-1
5	that	that	B-SBAR	IN	O	4	NMOD	-1
6	localized	localize	B-NP	VBN	O	7	NMOD	0
7	delivery	delivery	I-NP	NN	O	15	SUB	0
8	of	of	B-PP	IN	O	7	NMOD	-1
9	angiogenic	angiogenic	B-NP	JJ	B-protein	10	NMOD	3	angiogenic
10	factors	factor	I-NP	NNS	I-protein	8	PMOD	-1
11	via	via	B-PP	IN	O	7	NMOD	0
12	virus-mediated	virus-mediated	B-NP	JJ	O	14	NMOD	-1
13	gene	gene	I-NP	NN	O	14	NMOD	-1
14	transfer	transfer	I-NP	NN	O	11	PMOD	-1
15	may	may	B-VP	MD	O	5	SBAR	-1
16	be	be	I-VP	VB	O	15	VC	-1
17	useful	useful	B-ADJP	JJ	O	16	PRD	-1
18	in	in	B-PP	IN	O	17	AMOD	-1
19	the	the	B-NP	DT	O	20	NMOD	-1
20	treatment	treatment	I-NP	NN	O	18	PMOD	0
21	of	of	B-PP	IN	O	20	NMOD	-1
22	ischemic	ischemic	B-NP	JJ	O	23	NMOD	-1
23	disorders	disorder	I-NP	NNS	O	21	PMOD	-1
24	,	,	O	,	O	2	VMOD	-1
25	the	the	B-NP	DT	O	27	NMOD	-1
26	replication-deficient	replication-deficient	I-NP	JJ	O	27	NMOD	-1
27	adenovirus	adenovirus	I-NP	NN	O	32	NMOD	-1
28	(	(	O	(	O	30	DEP	-1
29	Ad	Ad	B-NP	NN	O	30	DEP	-1
30	)	)	O	)	O	27	NMOD	-1
31	vector	vector	B-NP	NN	O	32	NMOD	-1
32	AdCMV.VEGF165	AdCMV.VEGF165	I-NP	NN	O	24	PMOD	-1
33	(	(	O	(	O	32	NMOD	-1
34	where	where	B-ADVP	WRB	O	61	VMOD	-1
35	CMV	CMV	B-NP	NN	O	36	SUB	-1
36	is	be	B-VP	VBZ	O	34	SBAR	-1
37	cytomegalovirus	cytomegalovirus	B-NP	NN	O	39	NMOD	-1
38	and	and	I-NP	CC	O	39	NMOD	-1
39	VEGF	VEGF	I-NP	NN	B-protein	36	PRD	-1
40	is	be	B-VP	VBZ	O	61	VMOD	-1
41	vascular	vascular	B-NP	JJ	O	44	NMOD	-1
42	endothelial	endothelial	I-NP	JJ	O	44	NMOD	-1
43	growth	growth	I-NP	NN	O	44	NMOD	0
44	factor	factor	I-NP	NN	O	61	SUB	-1
45	)	)	O	)	O	44	NMOD	-1
46	containing	contain	B-VP	VBG	O	61	VMOD	-1
47	the	the	B-NP	DT	O	48	NMOD	-1
48	cDNA	cDNA	I-NP	NN	B-DNA	46	OBJ	-1
49	for	for	B-PP	IN	O	46	VMOD	-1
50	human	human	B-NP	JJ	B-protein	51	NMOD	-1
51	VEGF165	VEGF165	I-NP	NN	I-protein	49	PMOD	-1
52	,	,	O	,	O	61	P	-1
53	a	a	B-NP	DT	O	59	NMOD	-1
54	secreted	secrete	I-NP	VBN	O	59	NMOD	0
55	endothelial	endothelial	I-NP	JJ	B-protein	59	NMOD	-1
56	cell-specific	cell-specific	I-NP	JJ	I-protein	59	NMOD	-1
57	angiogenic	angiogenic	I-NP	JJ	I-protein	59	NMOD	3	angiogenic
58	growth	growth	I-NP	NN	I-protein	59	NMOD	0
59	factor	factor	I-NP	NN	I-protein	61	SUB	-1
60	,	,	O	,	O	59	P	-1
61	was	be	B-VP	VBD	O	33	SBAR	-1
62	constructed	construct	I-VP	VBN	O	61	VC	0
63	.	.	O	.	O	2	P	-1

1	Human	Human	B-NP	JJ	B-cell_line	5	NMOD	-1
2	umbilical	umbilical	I-NP	JJ	I-cell_line	5	NMOD	-1
3	vein	vein	I-NP	NN	I-cell_line	5	NMOD	-1
4	endothelial	endothelial	I-NP	JJ	I-cell_line	5	NMOD	-1
5	cells	cell	I-NP	NNS	I-cell_line	14	NMOD	-1
6	(	(	O	(	O	8	DEP	-1
7	HUVECs	HUVEC	B-NP	NNS	B-cell_line	8	DEP	-1
8	)	)	O	)	O	5	NMOD	-1
9	and	and	O	CC	O	14	NMOD	-1
10	rat	rat	B-NP	NN	B-cell_type	14	NMOD	-1
11	aorta	aorta	I-NP	NN	I-cell_type	14	NMOD	-1
12	smooth	smooth	I-NP	JJ	I-cell_type	14	NMOD	-1
13	muscle	muscle	I-NP	NN	I-cell_type	14	NMOD	-1
14	cells	cell	I-NP	NNS	I-cell_type	33	SUB	-1
15	(	(	O	(	O	17	DEP	-1
16	RASMCs	RASMC	B-NP	NNS	B-cell_type	17	DEP	-1
17	)	)	O	)	O	14	NMOD	-1
18	infected	infect	B-VP	VBN	O	14	NMOD	19	infected
19	with	with	B-PP	IN	O	18	VMOD	-1
20	AdCMV.VEGF165	AdCMV.VEGF165	B-NP	NN	O	26	NMOD	-1
21	(	(	O	(	O	26	NMOD	-1
22	5	5	B-NP	CD	O	24	AMOD	-1
23	and	and	I-NP	CC	O	24	AMOD	-1
24	20	20	I-NP	CD	O	26	NMOD	-1
25	plaque-forming	plaque-forming	I-NP	JJ	O	26	NMOD	-1
26	units	unit	I-NP	NNS	O	19	PMOD	-1
27	[	[	O	(	O	29	DEP	-1
28	pfu	pfu	B-NP	NN	O	29	DEP	-1
29	]	]	O	)	O	14	NMOD	-1
30	per	per	B-PP	IN	O	14	NMOD	-1
31	cell	cell	B-NP	NN	O	30	PMOD	-1
32	)	)	O	)	O	14	NMOD	-1
33	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT	-1
34	VEGF	VEGF	B-NP	NN	B-RNA	36	NMOD	-1
35	mRNA	mRNA	I-NP	NN	I-RNA	36	NMOD	0
36	expression	expression	I-NP	NN	O	39	NMOD	10	expression
37	and	and	O	CC	O	39	NMOD	-1
38	protein	protein	B-NP	NN	O	39	NMOD	-1
39	secretion	secretion	I-NP	NN	O	33	OBJ	14	secretion
40	into	into	B-PP	IN	O	39	NMOD	-1
41	the	the	B-NP	DT	O	42	NMOD	-1
42	supernatant	supernatant	I-NP	NN	O	40	PMOD	-1
43	.	.	O	.	O	33	P	-1

1	Furthermore	Furthermore	B-ADVP	RB	O	9	VMOD	-1
2	,	,	O	,	O	9	P	-1
3	the	the	B-NP	DT	O	5	NMOD	-1
4	conditioned	condition	I-NP	VBN	O	5	NMOD	-1
5	medium	medium	I-NP	NN	O	9	SUB	-1
6	from	from	B-PP	IN	O	5	NMOD	-1
7	these	these	B-NP	DT	O	8	NMOD	-1
8	cells	cell	I-NP	NNS	O	6	PMOD	-1
9	enhanced	enhance	B-VP	VBD	O	0	ROOT	17	enhanced
10	vascular	vascular	B-NP	JJ	O	11	NMOD	-1
11	permeability	permeability	I-NP	NN	O	9	OBJ	-1
12	in	in	B-ADVP	FW	O	9	VMOD	-1
13	vivo	vivo	I-ADVP	FW	O	12	AMOD	-1
14	.	.	O	.	O	9	P	-1

1	In	In	B-PP	IN	O	10	VMOD	-1
2	contrast	contrast	B-NP	NN	O	1	PMOD	-1
3	,	,	O	,	O	10	P	-1
4	neither	neither	O	CC	O	9	NMOD	-1
5	VEGF	VEGF	B-NP	NN	B-RNA	6	NMOD	-1
6	mRNA	mRNA	I-NP	NN	I-RNA	9	NMOD	0
7	nor	nor	O	CC	O	9	NMOD	-1
8	secreted	secrete	B-NP	VBN	O	9	NMOD	14	secreted
9	protein	protein	I-NP	NN	O	10	SUB	-1
10	was	be	B-VP	VBD	O	0	ROOT	-1
11	found	find	I-VP	VBN	O	10	VC	0
12	in	in	B-PP	IN	O	11	VMOD	-1
13	uninfected	uninfected	B-NP	JJ	B-cell_line	14	NMOD	19	uninfected
14	HUVECs	HUVEC	I-NP	NNS	I-cell_line	16	NMOD	-1
15	or	or	I-NP	CC	O	16	NMOD	-1
16	RASMCs	RASMC	I-NP	NNS	B-cell_type	12	PMOD	-1
17	or	or	B-PP	CC	O	12	PMOD	-1
18	in	in	B-PP	IN	O	12	PMOD	-1
19	cells	cell	B-NP	NNS	O	18	PMOD	-1
20	infected	infect	B-VP	VBN	O	19	NMOD	19	infected
21	with	with	B-PP	IN	O	20	VMOD	-1
22	the	the	B-NP	DT	O	25	NMOD	-1
23	control	control	I-NP	NN	O	25	NMOD	0
24	vector	vector	I-NP	NN	O	25	NMOD	-1
25	AdCMV.beta	AdCMV.beta	I-NP	NN	O	21	PMOD	-1
26	gal	gal	B-ADJP	JJ	O	25	NMOD	-1
27	(	(	O	(	O	33	DEP	-1
28	where	where	B-ADVP	WRB	O	33	DEP	-1
29	beta	beta	B-NP	NN	B-protein	30	NMOD	-1
30	gal	gal	I-NP	NN	I-protein	31	SUB	-1
31	is	be	B-VP	VBZ	O	28	SBAR	-1
32	beta-galactosidase	beta-galactosidase	B-NP	NN	B-protein	31	PRD	-1
33	)	)	O	)	O	26	AMOD	-1
34	.	.	O	.	O	10	P	-1

1	Assessment	Assessment	B-NP	NN	O	8	SUB	-1
2	of	of	B-PP	IN	O	1	NMOD	-1
3	starved	starve	B-NP	VBN	O	4	NMOD	-1
4	HUVECs	HUVEC	I-NP	NNS	B-cell_line	2	PMOD	-1
5	at	at	B-PP	IN	O	1	NMOD	-1
6	14	14	B-NP	CD	O	7	NMOD	-1
7	days	day	I-NP	NNS	O	5	PMOD	-1
8	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT	-1
9	sixfold	sixfold	B-NP	RB	O	10	AMOD	-1
10	more	more	I-NP	JJR	O	11	NMOD	-1
11	cells	cell	I-NP	NNS	O	8	OBJ	-1
12	for	for	B-PP	IN	O	11	NMOD	-1
13	AdCMV.VEGF165-infected	AdCMV.VEGF165-infected	B-NP	JJ	B-cell_line	14	NMOD	19	infected
14	HUVECs	HUVEC	I-NP	NNS	I-cell_line	12	PMOD	-1
15	(	(	O	(	O	20	DEP	-1
16	20	20	B-NP	CD	O	17	NMOD	-1
17	pfu	pfu	I-NP	NN	O	20	DEP	-1
18	per	per	B-PP	IN	O	17	NMOD	-1
19	cell	cell	B-NP	NN	O	18	PMOD	-1
20	)	)	O	)	O	11	NMOD	-1
21	than	than	B-PP	IN	O	11	NMOD	-1
22	for	for	B-PP	IN	O	21	PMOD	-1
23	either	either	B-NP	CC	O	28	NMOD	-1
24	infected	infected	I-NP	JJ	O	28	NMOD	19	infected
25	or	or	I-NP	CC	O	28	NMOD	-1
26	uninfected	uninfected	I-NP	JJ	B-cell_type	28	NMOD	19	uninfected
27	control	control	I-NP	NN	I-cell_type	28	NMOD	0
28	cells	cell	I-NP	NNS	I-cell_type	22	PMOD	-1
29	.	.	O	.	O	8	P	-1

1	RASMC	RASMC	B-NP	NN	O	2	NMOD	-1
2	proliferation	proliferation	I-NP	NN	O	3	SUB	1	proliferation
3	was	be	B-VP	VBD	O	0	ROOT	-1
4	unaffected	unaffected	B-ADJP	JJ	O	3	VC	16	unaffected
5	by	by	B-PP	IN	O	4	VMOD	-1
6	infection	infection	B-NP	NN	O	5	PMOD	19	infection
7	with	with	B-PP	IN	O	6	NMOD	-1
8	AdCMV.VEGF165	AdCMV.VEGF165	B-NP	NN	O	7	PMOD	-1
9	.	.	O	.	O	3	P	-1

1	When	When	B-ADVP	WRB	O	0	ROOT	-1
2	plated	plat	B-VP	VBN	O	1	SBAR	19	plated
3	in	in	B-PP	IN	O	2	VMOD	-1
4	2	2	B-NP	CD	O	5	AMOD	-1
5	%	%	I-NP	NN	O	6	NMOD	-1
6	serum	serum	I-NP	NN	O	3	PMOD	-1
7	on	on	B-PP	IN	O	2	VMOD	-1
8	dishes	dish	B-NP	NNS	O	7	PMOD	-1
9	precoated	precoate	B-VP	VBN	O	8	NMOD	-1
10	with	with	B-PP	IN	O	9	VMOD	-1
11	reconstituted	reconstitute	B-NP	VBN	O	13	NMOD	0
12	basement	basement	I-NP	NN	O	13	NMOD	-1
13	membrane	membrane	I-NP	NN	O	10	PMOD	-1
14	(	(	O	(	O	16	DEP	-1
15	Matrigel	Matrigel	B-NP	NN	O	16	DEP	-1
16	)	)	O	)	O	13	NMOD	-1
17	,	,	O	,	O	1	P	-1
18	HUVECs	HUVEC	B-NP	NNS	B-cell_line	17	NMOD	-1
19	infected	infect	B-VP	VBN	O	18	NMOD	19	infected
20	with	with	B-PP	IN	O	19	VMOD	-1
21	AdCMV.VEGF165	AdCMV.VEGF165	B-NP	NN	O	20	PMOD	-1
22	(	(	O	(	O	27	DEP	-1
23	20	20	B-NP	CD	O	24	NMOD	-1
24	pfu	pfu	I-NP	NN	O	27	DEP	-1
25	per	per	B-PP	IN	O	24	NMOD	-1
26	cell	cell	B-NP	NN	O	25	PMOD	-1
27	)	)	O	)	O	21	NMOD	-1
28	differentiated	differentiate	B-VP	VBN	O	21	NMOD	2	differentiated
29	into	into	B-PP	IN	O	28	VMOD	-1
30	capillary-like	capillary-like	B-NP	JJ	B-cell_line	31	NMOD	-1
31	structures	structure	I-NP	NNS	I-cell_line	29	PMOD	-1
32	.	.	O	.	O	18	P	-1

1	Under	Under	B-PP	IN	O	14	VMOD	-1
2	similar	similar	B-NP	JJ	O	3	NMOD	-1
3	conditions	condition	I-NP	NNS	O	1	PMOD	-1
4	,	,	O	,	O	14	P	-1
5	both	both	B-NP	DT	O	9	NMOD	-1
6	uninfected	uninfected	I-NP	JJ	B-cell_line	7	NMOD	19	uninfected
7	HUVECs	HUVEC	I-NP	NNS	I-cell_line	9	NMOD	-1
8	and	and	I-NP	CC	O	9	NMOD	-1
9	HUVECs	HUVEC	I-NP	NNS	B-cell_line	14	SUB	-1
10	infected	infect	B-VP	VBN	O	9	NMOD	19	infected
11	with	with	B-PP	IN	O	10	VMOD	-1
12	AdCMV.beta	AdCMV.beta	B-NP	NN	O	13	NMOD	-1
13	gal	gal	I-NP	NN	O	11	PMOD	-1
14	did	do	B-VP	VBD	O	0	ROOT	-1
15	not	not	I-VP	RB	O	14	VMOD	-1
16	differentiate	differentiate	I-VP	VB	O	14	VC	2	differentiate
17	.	.	O	.	O	14	P	-1

1	To	To	B-VP	TO	O	2	VMOD	-1
2	evaluate	evaluate	I-VP	VB	O	0	ROOT	-1
3	the	the	B-NP	DT	O	4	NMOD	-1
4	ability	ability	I-NP	NN	O	2	OBJ	0
5	of	of	B-PP	IN	O	4	NMOD	-1
6	AdCMV.VEGF165	AdCMV.VEGF165	B-NP	NN	O	5	PMOD	-1
7	to	to	B-VP	TO	O	8	VMOD	-1
8	function	function	I-VP	VB	O	4	NMOD	-1
9	in	in	B-ADVP	FW	O	8	VMOD	-1
10	vivo	vivo	I-ADVP	FW	O	9	AMOD	-1
11	,	,	O	,	O	13	P	-1
12	either	either	B-NP	DT	O	13	NMOD	-1
13	AdCMV	AdCMV	I-NP	NN	O	2	VMOD	-1
14	.	.	O	.	O	2	P	-1

1	VEGF165	VEGF165	B-NP	NN	B-protein	14	SUB	-1
2	or	or	I-NP	CC	O	14	VMOD	-1
3	AdCMV.beta	AdCMV.beta	I-NP	NN	O	4	NMOD	-1
4	gal	gal	I-NP	JJ	O	14	SUB	-1
5	(	(	O	(	O	13	DEP	-1
6	2	2	B-NP	CD	O	8	NMOD	-1
7	x	x	I-NP	CC	O	8	NMOD	-1
8	10	10	I-NP	CD	O	12	NMOD	-1
9	(	(	O	(	O	11	DEP	-1
10	10	10	B-NP	CD	O	11	DEP	-1
11	)	)	O	)	O	8	NMOD	-1
12	pfu	pfu	B-NP	NN	O	13	DEP	-1
13	)	)	O	)	O	4	NMOD	-1
14	was	be	B-VP	VBD	O	0	ROOT	-1
15	resuspended	resuspend	I-VP	VBN	O	14	VC	19	resuspended
16	in	in	B-PP	IN	O	15	VMOD	-1
17	0.5	0.5	B-NP	CD	O	19	NMOD	-1
18	mL	mL	I-NP	NN	O	19	NMOD	-1
19	Matrigel	Matrigel	I-NP	NNP	O	16	PMOD	-1
20	and	and	O	CC	O	19	NMOD	-1
21	injected	inject	B-VP	VBN	O	20	SBAR	19	injected
22	subcutaneously	subcutaneously	B-ADVP	RB	O	21	VMOD	-1
23	into	into	B-PP	IN	O	21	VMOD	-1
24	mice	mouse	B-NP	NNS	O	23	PMOD	-1
25	.	.	O	.	O	14	P	-1

1	Immunohistochemical	Immunohistochemical	B-NP	JJ	O	2	NMOD	-1
2	staining	staining	I-NP	NN	O	3	SUB	0
3	demonstrated	demonstrate	B-VP	VBD	O	21	VMOD	-1
4	VEGF	VEGF	B-NP	NN	B-protein	3	OBJ	-1
5	in	in	B-PP	IN	O	4	NMOD	-1
6	the	the	B-NP	DT	O	7	NMOD	-1
7	tissues	tissue	I-NP	NNS	O	5	PMOD	-1
8	surrounding	surround	B-VP	VBG	O	7	NMOD	-1
9	the	the	B-NP	DT	O	11	NMOD	-1
10	Matrigel	Matrigel	I-NP	NNP	O	11	NMOD	-1
11	plugs	plug	I-NP	NNS	O	8	OBJ	-1
12	containing	contain	B-VP	VBG	O	11	NMOD	-1
13	AdCMV.VEGF165	AdCMV.VEGF165	B-NP	NN	O	17	NMOD	-1
14	up	up	B-NP	IN	O	17	NMOD	-1
15	to	to	I-NP	TO	O	14	AMOD	-1
16	3	3	I-NP	CD	O	14	AMOD	-1
17	weeks	week	I-NP	NNS	O	12	OBJ	-1
18	after	after	B-PP	IN	O	12	VMOD	-1
19	injection	injection	B-NP	NN	O	18	PMOD	19	injection
20	,	,	O	,	O	21	P	-1
21	whereas	whereas	O	IN	O	0	ROOT	-1
22	no	no	B-NP	DT	O	23	NMOD	-1
23	VEGF	VEGF	I-NP	NN	B-protein	24	SUB	-1
24	was	be	B-VP	VBD	O	21	VMOD	-1
25	found	find	I-VP	VBN	O	24	VC	0
26	in	in	B-PP	IN	O	25	VMOD	-1
27	the	the	B-NP	DT	O	29	NMOD	-1
28	control	control	I-NP	NN	O	29	NMOD	0
29	plugs	plug	I-NP	NNS	O	26	PMOD	-1
30	with	with	B-PP	IN	O	29	NMOD	-1
31	AdCMV.beta	AdCMV.beta	B-NP	NN	B-protein	32	NMOD	-1
32	gal	gal	I-NP	NN	I-protein	30	PMOD	-1
33	.	.	O	.	O	21	P	-1

1	Two	Two	B-NP	CD	O	2	NMOD	-1
2	weeks	week	I-NP	NNS	O	3	PMOD	-1
3	after	after	B-PP	IN	O	7	VMOD	-1
4	injection	injection	B-NP	NN	O	3	PMOD	0
5	,	,	O	,	O	7	P	-1
6	there	there	B-NP	EX	O	7	SUB	-1
7	was	be	B-VP	VBD	O	21	VMOD	-1
8	histological	histological	B-NP	JJ	O	9	NMOD	-1
9	evidence	evidence	I-NP	NN	O	7	PRD	-1
10	of	of	B-PP	IN	O	9	NMOD	-1
11	neovascularization	neovascularization	B-NP	NN	O	10	PMOD	3	neovascularization
12	in	in	B-PP	IN	O	11	NMOD	-1
13	the	the	B-NP	DT	O	14	NMOD	-1
14	tissues	tissue	I-NP	NNS	O	12	PMOD	-1
15	surrounding	surround	B-VP	VBG	O	14	NMOD	-1
16	the	the	B-NP	DT	O	17	NMOD	-1
17	Matrigel	Matrigel	I-NP	NNP	O	15	OBJ	-1
18	containing	contain	B-VP	VBG	O	17	NMOD	-1
19	AdCMV.VEGF165	AdCMV.VEGF165	B-NP	NN	O	18	OBJ	-1
20	,	,	O	,	O	21	P	-1
21	whereas	whereas	O	IN	O	0	ROOT	-1
22	no	no	B-NP	DT	O	24	NMOD	-1
23	significant	significant	I-NP	JJ	O	24	NMOD	-1
24	angiogenesis	angiogenesis	I-NP	NN	O	25	SUB	3	angiogenesis
25	was	be	B-VP	VBD	O	21	VMOD	-1
26	observed	observe	I-VP	VBN	O	25	VC	0
27	in	in	B-PP	IN	O	26	VMOD	-1
28	response	response	B-NP	NN	O	27	PMOD	16	response
29	to	to	B-PP	TO	O	28	NMOD	-1
30	AdCMV.beta	AdCMV.beta	B-NP	NN	B-protein	31	NMOD	-1
31	gal	gal	I-NP	NN	I-protein	29	PMOD	-1
32	.	.	O	.	O	21	P	-1

1	Furthermore	Furthermore	B-ADVP	RB	O	8	VMOD	-1
2	,	,	O	,	O	8	P	-1
3	the	the	B-NP	DT	O	5	NMOD	-1
4	Matrigel	Matrigel	I-NP	NNP	O	5	NMOD	-1
5	plugs	plug	I-NP	NNS	O	8	SUB	-1
6	with	with	B-PP	IN	O	5	NMOD	-1
7	AdCMV.VEGF165	AdCMV.VEGF165	B-NP	NN	O	6	PMOD	-1
8	demonstrated	demonstrate	B-VP	VBD	O	0	ROOT	-1
9	hemoglobin	hemoglobin	B-NP	NN	B-protein	10	NMOD	-1
10	content	content	I-NP	NN	O	12	AMOD	-1
11	fourfold	fourfold	B-ADJP	RB	O	12	AMOD	-1
12	higher	high	I-ADJP	JJR	O	8	OBJ	-1
13	than	than	B-PP	IN	O	12	AMOD	-1
14	the	the	B-NP	DT	O	15	NMOD	-1
15	plugs	plug	I-NP	NNS	O	13	PMOD	-1
16	with	with	B-PP	IN	O	15	NMOD	-1
17	AdCMV.beta	AdCMV.beta	B-NP	NN	B-protein	18	NMOD	-1
18	gal	gal	I-NP	NN	I-protein	16	PMOD	-1
19	.	.	O	.	O	8	P	-1

1	Together	Together	B-ADVP	RB	O	10	VMOD	-1
2	,	,	O	,	O	10	P	-1
3	these	these	B-NP	DT	O	9	NMOD	-1
4	in	in	I-NP	FW	O	5	AMOD	-1
5	vitro	vitro	I-NP	FW	O	9	NMOD	-1
6	and	and	O	CC	O	9	NMOD	-1
7	in	in	B-NP	FW	O	8	AMOD	-1
8	vivo	vivo	I-NP	FW	O	9	NMOD	-1
9	studies	study	I-NP	NNS	O	10	SUB	-1
10	are	be	B-VP	VBP	O	0	ROOT	-1
11	consistent	consistent	B-ADJP	JJ	O	10	PRD	-1
12	with	with	B-PP	IN	O	11	AMOD	-1
13	the	the	B-NP	DT	O	14	NMOD	-1
14	concept	concept	I-NP	NN	O	12	PMOD	-1
15	that	that	B-SBAR	IN	O	14	NMOD	-1
16	Ad	Ad	B-NP	NN	O	17	NMOD	-1
17	vectors	vector	I-NP	NNS	O	18	SUB	-1
18	may	may	B-VP	MD	O	15	SBAR	-1
19	provide	provide	I-VP	VB	O	18	VC	-1
20	a	a	B-NP	DT	O	22	NMOD	-1
21	useful	useful	I-NP	JJ	O	22	NMOD	-1
22	strategy	strategy	I-NP	NN	O	19	OBJ	-1
23	for	for	B-PP	IN	O	22	NMOD	-1
24	efficient	efficient	B-NP	JJ	O	26	NMOD	-1
25	local	local	I-NP	JJ	O	26	NMOD	-1
26	delivery	delivery	I-NP	NN	O	23	PMOD	0
27	of	of	B-PP	IN	O	26	NMOD	-1
28	VEGF165	VEGF165	B-NP	NN	B-protein	27	PMOD	-1
29	in	in	B-PP	IN	O	22	NMOD	-1
30	the	the	B-NP	DT	O	31	NMOD	-1
31	treatment	treatment	I-NP	NN	O	29	PMOD	0
32	of	of	B-PP	IN	O	31	NMOD	-1
33	ischemic	ischemic	B-NP	JJ	O	34	NMOD	-1
34	diseases	disease	I-NP	NNS	O	32	PMOD	-1
35	.	.	O	.	O	10	P	-1

